BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22918737)

  • 21. Trimucytin: a collagen-like aggregating inducer isolated from Trimeresurus mucrosquamatus snake venom.
    Teng CM; Ko FN; Tsai IH; Hung ML; Huang TF
    Thromb Haemost; 1993 Mar; 69(3):286-92. PubMed ID: 8470053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet collagen receptors.
    Clemetson KJ; Clemetson JM
    Thromb Haemost; 2001 Jul; 86(1):189-97. PubMed ID: 11487007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A discrete sequence in a platelet integrin is involved in ligand recognition.
    D'Souza SE; Ginsberg MH; Matsueda GR; Plow EF
    Nature; 1991 Mar; 350(6313):66-8. PubMed ID: 2002847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct roles of GPVI and integrin alpha(2)beta(1) in platelet shape change and aggregation induced by different collagens.
    Jarvis GE; Atkinson BT; Snell DC; Watson SP
    Br J Pharmacol; 2002 Sep; 137(1):107-17. PubMed ID: 12183336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of α2β1 integrin inhibitor VP-i with anti-platelet properties in the venom of Vipera palaestinae.
    Arlinghaus FT; Momic T; Ammar NA; Shai E; Spectre G; Varon D; Marcinkiewicz C; Heide H; Lazarovici P; Eble JA
    Toxicon; 2013 Mar; 64():96-105. PubMed ID: 23319078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and characterization of a collagen-induced platelet aggregation inhibitor, triplatin, from salivary glands of the assassin bug, Triatoma infestans.
    Morita A; Isawa H; Orito Y; Iwanaga S; Chinzei Y; Yuda M
    FEBS J; 2006 Jul; 273(13):2955-62. PubMed ID: 16759235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting glycoprotein VI and the immunoreceptor tyrosine-based activation motif signaling pathway.
    Stegner D; Haining EJ; Nieswandt B
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1615-20. PubMed ID: 24925975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Function of glycoprotein VI and integrin alpha2beta1 in the procoagulant response of single, collagen-adherent platelets.
    Heemskerk JW; Siljander P; Vuist WM; Breikers G; Reutelingsperger CP; Barnes MJ; Knight CG; Lassila R; Farndale RW
    Thromb Haemost; 1999 May; 81(5):782-92. PubMed ID: 10365754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Platelet GPVI Plus rt-PA Administration but Not α2β1-Mediated Collagen Binding Protects against Ischemic Brain Damage in Mice.
    Schuhmann MK; Kraft P; Bieber M; Kollikowski AM; Schulze H; Nieswandt B; Pham M; Stegner D; Stoll G
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31022936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet GPVI: a target for antithrombotic therapy?!
    Dütting S; Bender M; Nieswandt B
    Trends Pharmacol Sci; 2012 Nov; 33(11):583-90. PubMed ID: 22901552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet receptors for collagen.
    Moroi M; Jung SM
    Thromb Haemost; 1997 Jul; 78(1):439-44. PubMed ID: 9198193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs.
    Gachet C
    Pharmacol Ther; 2005 Nov; 108(2):180-92. PubMed ID: 15955565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different regions of the class P-III snake venom metalloproteinase jararhagin are involved in binding to alpha2beta1 integrin and collagen.
    Tanjoni I; Evangelista K; Della-Casa MS; Butera D; Magalhães GS; Baldo C; Clissa PB; Fernandes I; Eble J; Moura-da-Silva AM
    Toxicon; 2010 Jun; 55(6):1093-9. PubMed ID: 20056118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet collagen receptors: a new target for inhibition?
    Clemetson KJ
    Haemostasis; 1999 Sep; 29(1):16-26. PubMed ID: 10494031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GPVI and alpha2beta1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow.
    Sarratt KL; Chen H; Zutter MM; Santoro SA; Hammer DA; Kahn ML
    Blood; 2005 Aug; 106(4):1268-77. PubMed ID: 15886326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New advances in treating thrombotic diseases: GPVI as a platelet drug target.
    Jiang P; Jandrot-Perrus M
    Drug Discov Today; 2014 Sep; 19(9):1471-5. PubMed ID: 24931218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rhinocetin, a venom-derived integrin-specific antagonist inhibits collagen-induced platelet and endothelial cell functions.
    Vaiyapuri S; Hutchinson EG; Ali MS; Dannoura A; Stanley RG; Harrison RA; Bicknell AB; Gibbins JM
    J Biol Chem; 2012 Jul; 287(31):26235-44. PubMed ID: 22689571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomimetic design of platelet adhesion inhibitors to block integrin α2β1-collagen interactions: II. Inhibitor library, screening, and experimental validation.
    Zhang L; Zhang C; Sun Y
    Langmuir; 2014 Apr; 30(16):4734-42. PubMed ID: 24697658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mouse antithrombotic assay. Inhibition of platelet thromboembolism by disintegrins.
    Beviglia L; Poggi A; Rossi C; McLane MA; Calabrese R; Scanziani E; Cook JJ; Niewiarowski S
    Thromb Res; 1993 Aug; 71(4):301-15. PubMed ID: 8236159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomimetic design of platelet adhesion inhibitors to block integrin α2β1-collagen interactions: I. Construction of an affinity binding model.
    Zhang L; Sun Y
    Langmuir; 2014 Apr; 30(16):4725-33. PubMed ID: 24697616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.